Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

159.37 +3.17 (+2.03%)
Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization. 
Via Benzinga
Topics Government
Exposures Political
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
LabCorp Q3 2024 EPS beats expectations at $3.50, with 7.4% revenue growth to $3.28B. Adjusted EPS guidance revised due to weather. 
Via Benzinga
Topics Earnings
Exposures Financial
This Snap Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
What Analysts Are Saying About Quest Diagnostics Stock
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
Via Benzinga
Earnings Preview: Quest Diagnostics
Via Benzinga
Looking Into Quest Diagnostics's Recent Short Interest
Via Benzinga
Decoding 7 Analyst Evaluations For Quest Diagnostics
Via Benzinga
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, citing acquisitions and new customer wins. 
Via Benzinga
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
What Analysts Are Saying About Quest Diagnostics Stock
Via Benzinga
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
Via Benzinga
Uncovering Dividend Opportunities with NYSE:DGX.
Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential. 
Via Chartmill
5 Analysts Assess Quest Diagnostics: What You Need To Know
Via Benzinga
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024... 
Via Benzinga
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 revenue... 
Via Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024
DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist
The market mood turned jittery after Monday’s rebound, with index futures trading on either side of the unchanged line early Tuesday. The apprehensions reflect uncertainties regarding geopolitics,... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday?
Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphabet Inc. and Tesla Inc. 
Via Benzinga
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
Via Benzinga
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
Via Benzinga
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing... 
Via Benzinga
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.